Intuitive Surgical sinks on insurance coverage warning
Intuitive Surgical reported Q2 non-GAAP EPS of $2.80 on revenue of $2.89 billion, beating analyst estimates, while warning that insurance coverage changes modestly slowed U.S. procedure growth. The company reaffirmed its full-year Da Vinci procedure growth forecast of 13.5% to 15.5% and raised its non-GAAP gross margin outlook to 68% to 69%.
*this image is generated using AI for illustrative purposes only.
Intuitive Surgical Inc. stock fell more than 11% in premarket trading after the robotic surgery company reported second-quarter 2026 financial results that topped Wall Street estimates but included warnings about slower U.S. procedure growth due to changes in insurance coverage. The company maintained its full-year procedure growth outlook and raised its gross margin guidance, yet investors reacted negatively to commentary regarding the impact of expiring Affordable Care Act premium subsidies on patient care decisions.
Q2 Financial Performance
Intuitive Surgical reported non-GAAP earnings of $2.80 per share, beating the consensus estimate of $2.50 by 12%. Revenue increased 19% year over year to $2.89 billion, exceeding analyst expectations of $2.82 billion. Recurring revenue grew 19% to $2.47 billion, accounting for 85% of total revenue. Adjusted gross margin improved to 70% from 67.9% in the prior year, aided by lower product costs, fixed-cost leverage, and a $36 million benefit from tariff refunds. GAAP net income was $818 million, or $2.29 per share, compared to $658 million, or $1.81 per share, in the same period last year.
| Metric | Q2 2026 Result | Analyst Estimate |
|---|---|---|
| Non-GAAP EPS | $2.80 | $2.50 |
| Revenue | $2.89 billion | $2.82 billion |
| Recurring Revenue | $2.47 billion | — |
| Non-GAAP Gross Margin | 70% | — |
| Non-GAAP Operating Margin | 42% | — |
| GAAP Net Income | $818 million | — |
| GAAP EPS | $2.29 | — |
Operational Highlights and Procedure Growth
The company reported broad-based procedure growth, with total procedures increasing 16%. Da Vinci procedures rose 15% year over year, while Ion procedures surged 36%. In the U.S., Da Vinci procedure growth was 12%, led by general surgery, while international growth reached 20%. Europe and Asia each grew 20%, with rest-of-world markets up 22%. Ion procedures reached 48,000 in the quarter, bringing the cumulative total to over 400,000. SP procedures grew 61%, driven by strength in the U.S. and Korea.
| Procedure Category | Q2 2026 Growth |
|---|---|
| Total Procedures | ~16% YoY |
| Da Vinci Procedures | ~15% YoY |
| Ion Procedures | ~36% YoY |
| SP Procedures | ~61% YoY |
| US Da Vinci Procedures | ~12% YoY |
| OUS Da Vinci Procedures | ~20% YoY |
System Placements and Installed Base
Da Vinci system placements totaled 468 in Q2 2026, up 18% from 395 in the prior year, including 246 Da Vinci 5 systems. The installed base of Da Vinci 5 surpassed 1,700 systems. Ion system placements were 55 compared to 54 in the year-ago period. SP system placements reached 38, up from 23 last year, bringing the global SP installed base to 445 systems. In the U.S., 267 systems were placed, up 24% from last year, while international placements increased 12% to 201.
| System | June 30, 2026 | June 30, 2025 | Change (%) |
|---|---|---|---|
| Da Vinci Surgical Systems | 11,710 | 10,488 | +12% |
| Ion Endoluminal Systems | 1,096 | 905 | +21% |
Revenue Breakdown
Systems revenue for the Da Vinci business grew 19% to $685 million. Total instruments and accessories revenue grew 18% to $1.73 billion. Da Vinci instruments and accessories revenue per procedure increased to approximately $1,830 compared to $1,800 in the prior year, driven by a higher mix of SP and Da Vinci 5 procedures. Service revenue increased 21% to $472 million. The average selling price for purchased Da Vinci systems was $1.6 million, compared to $1.5 million last year. Lease buyout revenue was $56 million compared to $30 million last year.
| Revenue Segment | Q2 2026 | YoY Change |
|---|---|---|
| Total Revenue | $2.89 billion | +19% |
| Recurring Revenue | $2.47 billion | +19% |
| INA Revenue | $1.73 billion | +18% |
| Systems Revenue (Da Vinci) | $685 million | +19% |
| Service Revenue | $472 million | +21% |
Strategic Initiatives and Outlook
Management highlighted the Extended Use Program (EUP), expected to launch in the first half of 2027, which aims to increase instrument uses for high-volume benign procedures to reduce costs. The company also submitted for FDA 510(k) clearance a next-generation flexible robotic endoscope system. Da Vinci 5 clearance was received in India during the quarter.
For the full year 2026, Intuitive Surgical reaffirmed its Da Vinci procedure growth forecast of 13.5% to 15.5%, with expectations to be closer to the midpoint. The company raised its non-GAAP gross margin outlook to a range of 68% to 69% of revenue, up from the previous 67.5% to 68.5%. Non-GAAP operating expense growth is expected to be between 11% and 13%.
| Outlook Metric | Updated 2026 Guidance |
|---|---|
| Da Vinci Procedure Growth | 13.5%–15.5% (near midpoint) |
| Non-GAAP Gross Margin | 68%–69% of revenue |
| Non-GAAP OpEx Growth | 11%–13% |
Balance Sheet and Cash Flow
Intuitive Surgical ended the quarter with $8.6 billion in cash and investments, up from $8 billion in the previous quarter. Free cash flow in the first half of 2026 was $1.8 billion, an increase of 71% compared to the first six months of 2025. Cash flow from operations was partially offset by stock repurchases of $379 million at an average price of $430 and capital expenditures of $112 million.
How will the potential expiration of Affordable Care Act premium subsidies specifically impact patient volumes in the second half of 2026?
What is the anticipated revenue impact and market adoption timeline for the Extended Use Program (EUP) launching in the first half of 2027?
Can the strong international growth of 20% offset any prolonged softness in U.S. procedure growth driven by insurance headwinds?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
